NK-1 antagonists and itch

Handbook of Experimental Pharmacology

Volumn 226, Issue , 2015, Pages 237-255

  Ständer, Sonja ^a   Luger, Thomas A ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antagonist; Antinociception; G protein coupled receptor; Keratinocyte; Mast cell; Neurokinin 1 receptor; Neuropeptides; Prurigo; Pruritus; Sensory C fiber; Skin; Substance P; Tachykinins

Indexed keywords

APREPITANT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TACHYKININ; MORPHOLINE DERIVATIVE;

ACUTE PRURITUS; ANTIPRURITIC EFFECT; ARTICLE; ASTHENIA; ATOPIC DERMATITIS; BRACHIORADIAL PRURITUS; CHRONIC PRURITUS; CUTANEOUS T CELL LYMPHOMA; DROWSINESS; DRUG EFFECT; DRUG INDUCED PRURITUS; DRUG TARGETING; FATIGUE; FIBROBLAST; HEADACHE; HUMAN; INFLAMMATION; KERATINOCYTE; MEDIATOR RELEASE; NAUSEA; NEURODERMATITIS; NEUROPATHIC PRURITUS; NONHUMAN; PARANEOPLASTIC PRURITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PRURITUS; SCRATCHING; SEZARY SYNDROME; SOMNOLENCE; VERTIGO; ANIMAL; ANTAGONISTS AND INHIBITORS; PHYSIOLOGY;

ANIMALS; HUMANS; MORPHOLINES; PRURITUS; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 84928015854     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-662-44605-8_14     Document Type: Article

References (99)

1. Abadía Molina F, Burrows NP, Jones RR, Terenghi G, Polak JM (1992) Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis. Br J Dermatol 127: 344-351.
2. Akiyama T, Tominaga M, Davoodi A, Nagamine M, Blansit K, Horwitz A, Carstens MI, Carstens E (2013) Roles for substance P and gastrin-releasing peptide as neurotransmitters released by primary afferent pruriceptors. J Neurophysiol 109: 742-748.
3. Ally MS, Gamba CS, Peng DH, Tang JY (2013) The use of aprepitant in brachioradial pruritus. JAMA Dermatol 149: 627-628.
4. Alysandratos KD, Asadi S, Angelidou A, Zhang B, Sismanopoulos N, Yang H, Critchfield A, Theoharides TC (2012) Neurotensin and CRH interactions augment human mast cell activation. PLoS One 7: e48934.
5. Amatya B, Nordlind K, Wahlgren CF (2010) Responses to intradermal injections of substance P in psoriasis patients with pruritus. Skin Pharmacol Physiol 23: 133-138.
6. Andoh T, Kuraishi Y (2002) Inhibitory effects of azelastine on substance P-induced itchassociated response in mice. Eur J Pharmacol 436: 235-239.
7. Andoh T, Nagasawa T, Satoh M, Kuraishi Y (1998) Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther 286: 1140-1145.
8. Andoh T, Katsube N, Maruyama M, Kuraishi Y (2001) Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice. J Invest Dermatol 117: 1621-1626.
9. Asadi S, Alysandratos KD, Angelidou A, Miniati A, Sismanopoulos N, Vasiadi M, Zhang B, Kalogeromitros D, Theoharides TC (2012) Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol 132: 324-329.
10. Benecke H, Lotts T, Ständer S (2013a) Investigational drugs for pruritus. Expert Opin Investig Drugs 22: 1167-1179.
11. Benecke H, Wäring J, Ständer S (2013b) Transient receptor potential channels and pruritus. In: Bíro T, Szallasi A (eds) TRP channels in drug discovery, vol 2, Methods in pharmacology and toxicology series. Springer/Humana, New York, pp 255-277.
12. Böhm SK, Khitin LM, Smeekens SP, Grady EF, Payan DG, Bunnett NW (1997) Identification of potential tyrosine-containing endocytic motifs in the carboxyl-tail and seventh transmembrane domain of the neurokinin 1 receptor. J Biol Chem 272: 2363-2372.
13. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J (2011) Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 164: 665-667.
14. Bowden JJ, Garland AM, Baluk P, Lefevre P, Grady EF, Vigna SR, Bunnett NW, McDonald DM (1994) Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci USA 91: 8964-8968.
15. Burbach GJ, Kim KH, Zivony AS, Kim A, Aranda J, Wright S, Naik SM, Caughman SW, Ansel JC, Armstrong CA (2001) The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol 117: 1075-1082.
16. Carstens EE, Carstens MI, Simons CT, Jinks SL (2010) Dorsal horn neurons expressing NK-1 receptors mediate scratching in rats. Neuroreport 21: 303-308.
17. Chang SE, Han SS, Jung HJ, Choi JH (2007) Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 156: 1272-1277.
18. Dando TM, Perry C (2004) Aprepitant: a review of its use in the prevention of chemotherapyinduced nausea and vomiting. Drugs 64: 777-794.
19. Datar P, Srivastava S, Coutinho E, Govil G (2004) Substance P: structure, function, and therapeutics. Curr Top Med Chem 4: 75-103.
20. De Vane CL (2001) Substance P: a new era, a new role. Pharmacotherapy 21: 1061-1069.
21. Duval A, Dubertret L (2009) Aprepitant as an antipruritic agent? N Engl J Med 361: 1415-1416.
22. Gerber PA, Buhren BA, Homey B (2011) More on aprepitant for erlotinib-induced pruritus. N Engl J Med 364: 486-487.
23. Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF (2006) Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 176: 2535-2540.
24. Haas S, Capellino S, Phan NQ, Böhm M, Luger TA, Straub RH, Ständer S (2010) Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci 58: 193-197.
25. Hägermark O, Hökfelt T, Pernow B (1978) Flare and itch induced by substance P in human skin. J Invest Dermatol 71: 233-235.
26. Harmar AJ, Armstrong A, Pascall JC, Chapman K, Rosie R, Curtis A, Going J, Edwards CRW, Fink G (1986) cDNA sequence of human beta-preprotachykinin, the common precursor to substance P and neurokinin A. FEBS Lett 208: 67-72.
27. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapyinduced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21: 4077-4080.
28. Hon KL, Lam MC, Wong KY, Leung TF, Ng PC (2007) Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. Br J Dermatol 157: 922-925.
29. Hosokawa C, Takeuchi S, Furue M (2009) Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride. J Dermatol 36: 185-190.
30. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, SchmelzM(2006) The neurobiology of itch. Nat Rev Neurosci 7: 535-547.
31. Imamachi N, Park GH, Lee H, Anderson DJ, Simon MI, Basbaum AI, Han SK (2009) TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci USA 106: 11330-11335.
32. Inagaki N, Shiraishi N, Igeta K, Nagao M, Kim JF, Chikumoto T, Itoh T, Katoh H, Tanaka H, Nagai H (2010) Depletion of substance P, a mechanism for inhibition of mouse scratching behavior by tacrolimus. Eur J Pharmacol 626: 283-289.
33. Janelsins BM, Mathers AR, Tkacheva OA, Erdos G, Shufesky WJ, Morelli AE, Larregina AT (2009) Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity. Blood 113: 3017-3026.
34. Janelsins BM, Sumpter TL, Tkacheva OA, Rojas-Canales DM, Erdos G, Mathers AR, Shufesky WJ, Storkus WJ, Falo LD Jr, Morelli AE, Larregina AT (2013) Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood 121: 2923-2933.
35. Järvikallio A, Harvima IT, Naukkarinen A (2003) Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 295: 2-7.
36. Johanek LM, Meyer RA, Hartke T, Hobelmann JG, Maine DN, LaMotte RH, Ringkamp M (2007) Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 27: 7490-7497.
37. Kähler CM, Sitte BA, Reinisch N, Wiedermann CJ (1993) Stimulation of the chemotactic migration of human fibroblasts by substance P. Eur J Pharmacol 249: 281-286.
38. Kawana S, Liang Z, Nagano M, Suzuki H (2006) Role of substance P in stress-derived degranulation of dermal mast cells in mice. J Dermatol Sci 42: 47-54.
39. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S (2006) Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59: 216-223.
40. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640-1645.
41. Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, Reiners KS, Raap U, van Buuren HR, van Erpecum KJ, Davies NA, Rust C, Engert A, Jalan R, Oude Elferink RP, Beuers U (2012) Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 56: 1391-1400.
42. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H (2010) Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25: 1251-1257.
43. Lai JP, Ho WZ, Kilpatrick LE, Wang X, Tuluc F, Korchak HM, Douglas SD (2006) Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation. Proc Natl Acad Sci USA 103: 7771-7776.
44. La Motte RH, Shimada SG, Green BG, Zelterman D (2009) Pruritic and nociceptive sensations and dysesthesias from a spicule of cowhage. J Neurophysiol 101: 1430-1443.
45. Lee JH, Cho SH (2011) Korean red ginseng extract ameliorates skin lesions in NC/Nga mice: an atopic dermatitis model. J Ethnopharmacol 133: 810-817.
46. Levêque D (2010) Aprepitant for erlotinib-induced pruritus. N Engl J Med 363: 1680-1681.
47. Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD (2012) Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology 116: 882-95.
48. Liu T, Ji RR (2013) New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms? Pflugers Arch 465: 1671-1685.
49. Liu JY, Zhao YZ, Peng C, Li FQ, Zhu QG, Hu JH (2008) Effect of cetirizine hydrochloride on the expression of substance P receptor and cytokines production in human epidermal keratinocytes and dermal fibroblasts. Yao Xue Xue Bao 43: 383-387.
50. Maintz L, Wardelmann E, Walgenbach K, Fimmers R, Bieber T, Raap U, Novak N (2011) Neuropeptide blood levels correlate with mast cell load in patients with mastocytosis. Allergy 66: 862-869.
51. Matterne U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Büttner M, Ofenloch R, Diepgen TL, Weisshaar E (2011) Prevalence, correlates and characteristics of chronic pruritus: a populationbased cross-sectional study. Acta Derm Venereol 91: 674-679.
52. Mir O, Coriat R (2012) Aprepitant for pruritus: drug-drug interactions matter. Lancet Oncol 13: 964-965.
53. Mir O, Blanchet B, Goldwasser F (2011) More on aprepitant for erlotinib-induced pruritus. N Engl J Med 364: 487.
54. Muñoz M, Rosso M, Robles-Frias MJ, Salinas-Martín MV, Rosso R, González-Ortega A, Coveñas R (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90: 1259-1269.
55. Nakamura M, Toyoda M, Morohashi M (2003) Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 149: 718-730.
56. Nazarian A, Tenayuca JM, Almasarweh F, Armendariz A, Are D (2014) Sex differences in formalin-evoked primary afferent release of substance P. Eur J Pain 18: 39-46.
57. Ohmura T, Hayashi T, Satoh Y, Konomi A, Jung B, Satoh H (2004) Involvement of substance P in scratching behaviour in an atopic dermatitis model. Eur J Pharmacol 491: 191-194.
58. Orel M, Padros E, Manyosa J (2012) Structural features of the C-terminus from the human neurokinin-1 receptor. FEBS J 279(13): 2357-2367.
59. Patacchini R, Lecci A, Holzer P, Maggi CA (2004) Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci 25: 1-3.
60. Pavlovic S, Daniltchenko M, Tobin DJ, Hagen E, Hunt SP, Klapp BF, Arck PC, Peters EM (2008) Further exploring the brain-skin connection: stress worsens dermatitis via substance P-dependent neurogenic inflammation in mice. J Invest Dermatol 128: 434-446.
61. Peters EM, Liotiri S, Bodo E, Hagen E, Bíro T, Arck PC, Paus R (2007) Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol 171: 1872-1886.
62. Ping F, Shang J, Zhou J, Song J, Zhang L (2012) Activation of neurokinin-1 receptor by substance P inhibits melanogenesis in B16-F10 melanoma cells. Int J Biochem Cell Biol 44: 2342-2348.
63. Pogatzki-Zahn E, Marziniak M, Schneider G, Luger TA, Ständer S (2008) Chronic pruritus: targets, mechanisms and future therapies. Drug News Perspect 21: 541-551.
64. Reich A, Orda A, Wiśnicka B, Szepietowski JC (2007) Plasma neuropeptides and perception of pruritus in psoriasis. Acta Derm Venereol 87: 299-304.
65. Remröd C, Lonne-Rahm S, Nordlind K (2007) Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res 299: 85-91.
66. Ruhlmann CH, Herrstedt J (2011) Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 10: 449-462.
67. Saeed AW, Ribeiro-da-Silva A (2013) De novo expression of neurokinin-1 receptors by spinoparabrachial lamina I pyramidal neurons following a peripheral nerve lesion. J Comp Neurol 521: 1915-1928.
68. Sahbaie P, Shi X, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, Clark JD (2009) Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision. Pain 145: 341-349.
69. Salomon J, Baran E (2008) The role of selected neuropeptides in pathogenesis of atopic dermatitis. J Eur Acad Dermatol Veneoreol 22: 223-228.
70. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G (2012) Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 13: 1020-1024.
71. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC (1998) Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 272: 81-96.
72. Scholzen TE, Ständer S, Riemann H, Brzoska T, Luger TA (2003) Modulation of cutaneous inflammation by angiotensin-converting enzyme. J Immunol 170: 3866-3873.
73. Scholzen TE, Steinhoff M, Sindrilaru A, Schwarz A, Bunnett NW, Luger TA, Armstrong CA, Ansel JC (2004) Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J 18: 1007-1009.
74. Serra J, Campero M, Bostock H, Ochoa J (2004) Two types of C nociceptors in human skin and their behavior in areas of capsaicin-induced secondary hyperalgesia. J Neurophysiol 91: 2770-2781.
75. Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blum RA (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44: 215-223.
76. Siepmann D, Weishaupt C, Luger TA, Ständer S (2011) Evaluation of the German guideline for chronic pruritus: results of a retrospective study on 385 patients. Dermatology 223: 374-380.
77. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC (1999) Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav Immun 13: 225-239.
78. Southwell BR, Seybold VS, Woodman HL, Jenkinson KM, Furness JB (1998) Quantitation of neurokinin 1 receptor internalization and recycling in guinea-pig myenteric neurons. Neuroscience 87: 925-931.
79. Ständer S, Weisshaar E (2012) Medical treatment of pruritus. Expert Opin Emerg Drugs 17: 335-345.
80. Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, Bergasa NV, Gieler U, Misery L, Wallengren J, Darsow U, Streit M, Metze D, Luger TA, Greaves MW, Schmelz M, Yosipovitch G, Bernhard JD (2007) Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 87: 291-294.
81. Ständer S, Siepmann D, Luger TA (2009) Targeting the neurokinin receptor 1 as a new antipruritic strategy: results of a case series with aprepitant. Acta Derm Venereol 89: 717.
82. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA (2010) Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 5: e10968.
83. Ständer S, Blome C, Breil B, Bruland P, Darsow U, Dugas M, Evers A, Fritz F, Metz M, Phan NQ, Raap U, Reich A, Schneider G, Steinke S, Szepietowski J, Weisshaar E, Augustin M (2012a) Assessment of pruritus-current standards and implications for clinical practice: consensus paper of the Action Group Pruritus Parameter of the National Working Group on Pruritus Research (AGP). Hautarzt 63: 521-531.
84. Ständer S, Darsow U, Mettang T, Gieler U, Maurer M, Ständer H, Beuers U, Niemeier V, Gollnick H, Vogelgsang M, Weisshaar E (2012b) S2k guideline-Chronic Pruritus. J Dtsch Dermatol Ges 4: S1-S27.
85. Takeda M, Takahashi M, Matsumoto S (2012) Suppression of neurokinin-1 receptor in trigeminal ganglia attenuates central sensitization following inflammation. J Peripher Nerv Syst 17: 169-181.
86. Tanaka T, Danno K, Ikai K, Imamura S (1988) Effects of substance P and substance K on the growth of cultured keratinocytes. J Invest Dermatol 90: 399-401.
87. Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J, Douglas SD (2011) A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One 6: e24180.
88. Teodoro FC, Tronco Júnior MF, Zampronio AR, Martini AC, Rae GA, Chichorro JG (2013) Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models. Neuropeptides 47: 199-206.
89. Thomsen JS, Sonne M, Benfeldt E, Jensen SB, Serup J, Menné T (2002) Experimental itch in sodium lauryl sulphate-inflamed and normal skin in humans: a randomized, double-blind, placebo-controlled study of histamine and other inducers of itch. Br J Dermatol 146: 792-800.
90. Torres T, Fernandes I, Selores M, Alves R, Lima M (2012) Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol 66: e14-e15.
91. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M (2002) Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 147: 71-79.
92. Trivedi M, Bergasa NV (2010) Serum concentrations of substance P in cholestasis. Ann Hepatol 9: 177-180.
93. Vincenzi B, Fratto ME, Santini D, Tonini G (2010a) Aprepitant against pruritus in patients with solid tumours. Support Care Cancer 18: 1229-1230.
94. Vincenzi B, Tonini G, Santini D (2010b) Aprepitant for erlotinib-induced pruritus. N Engl J Med 363: 397-398.
95. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, Petersen LJ, Schmelz M (2000) Acute effects of substance P and calcitonin gene-related peptide in human skin-a microdialysis study. J Invest Dermatol 115: 1015-1020.
96. Weisshaar E, Dalgard F (2009) Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 89: 339-350.
97. Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, Gieler U, Lotti T, Lambert J, Maisel P, Streit M, Greaves MW, Carmichael AJ, Tschachler E, Ring J, Ständer S (2012) European guideline on chronic pruritus. Acta Derm Venereol 92: 563-581.
98. Wong BJ, Minson CT (2011) Altered thermal hyperaemia in human skin by prior desensitization of neurokinin-1 receptors. Exp Physiol 96: 599-609.
99. Yamaoka J, Kawana S (2007) Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice. J Dermatol Sci 48: 123-32.